Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

Kentuckiana Cancer Institute20 enrolled

Overview

To determine if Iscar Quercus improves immune function and quality of life among patients with stage IV non-small cell lung cancer.

RAndomized pilot study of supplemental Iscar in combination with Gemcitabine vs. Gemcitabine alone as second line treatment for advanced non-small cell lung cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-Small Cell Lung Cancer

Interventions

Iscar QuercusDRUG

GemcitabineDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * newly diagnosed IIIB and IV NSCLC who have failed one prior line of chemo * Karnofsky score 60% or greater * patients who will be treated with Gemcitabine

Locations (1)

Kentuckiana Cancer Institute

Louisville, Kentucky, United States

Outcomes

Primary Outcomes

To determine if Iscar improves immune function and quality of life.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.